© Reuters. FILE PHOTO: Vials labelled “COVID-19 Coronavirus Vaccine” and sryinge are seen in front of displayed J&J logo in this illustration
(Reuters) – The United States expects to roll out three to four million doses of Johnson & Johnson (NYSE:)’s COVID-19 vaccine next week, pending authorization from the Food and Drug Administration, White House COVID-19 response coordinator Jeff Zients said on Wednesday.
A Johnson & Johnson executive on Tuesday had said the company expected to ship nearly 4 million doses of the vaccine once it gained authorization.
The additional vaccine will help President Joe Biden’s administration in its goal of ramping up vaccination across the country as it seeks to control the pandemic that has cost more than 500,000 lives in the United States and pummeled the economy.
Zients described J&J’s manufacturing as being behind schedule when the new president took over from former President Donald Trump.
“It was disappointing when we arrived. I think the progress is real and we look forward to continuing to work with the company to accelerate … their delivery and their capacity,” Zients told a briefing.
The FDA said on Wednesday that the Johnson & Johnson one-dose vaccine appeared safe and effective in trials, paving the way for its approval for emergency use as soon as this week.
The company has a contract to deliver 100 million doses to the United States by the end of June. Zients said the administration was working to accelerate that timeline.
Zients told reporters that the government had caught up from a backlog of vaccine distribution caused by the winter storm that hit Texas last week.
The White House also announced on Wednesday that it would deliver millions of masks next month to food banks and community health centers to ensure less well-off communities were getting access to a key tool to prevent the spread of COVID-19.
Zients said that effort would cost $86 million.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.